Interferon beta-1b

The use of interferons as potential disease-modifying agents in multiple sclerosis (MS) is discussed. The mechanisms by which interferon beta-1b produces therpeutic benefits are unknown, but several drug-related activities may be relevant to the immunopathogenesis of MS.

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 1994-10, Vol.344 (8929), p.1057-1060
Main Author: Goodkin, D.E.
Format: Article
Language:English
Subjects:
Antigens
Biological and medical sciences
Biological products
Cell culture
Clinical trials
Cytotoxicity
Drug dosages
Drug therapy
FDA approval
Humans
Immunomodulators
Interferon
Interferon beta-1a
Interferon beta-1b
Interferon-beta - adverse effects
Interferon-beta - therapeutic use
Magnetic resonance imaging
Medical research
Medical sciences
Multiple sclerosis
Multiple Sclerosis - therapy
Pharmacokinetics
Pharmacology
Pharmacology. Drug treatments
Recombinant Proteins - adverse effects
Recombinant Proteins - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The use of interferons as potential disease-modifying agents in multiple sclerosis (MS) is discussed. The mechanisms by which interferon beta-1b produces therpeutic benefits are unknown, but several drug-related activities may be relevant to the immunopathogenesis of MS.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(94)91713-2